Biomarin Pharmaceutical Inc. (0HNC)
LSE
Closed
Aug 21, 2026
Day's Range
66.6452 wk Range
49.39Overview - 0HNC - Biomarin Pharmaceutical Inc.
Key Statistics
Valuation
Enterprise Value
16.23B
P/E (Trailing)
‪3.10‬
Price / Book
‪2.04‬
EV / EBITDA
‪25.15‬
Profitability
Profit Margin
‪2.14%‬
Operating Margin
‪21.16%‬
Return on Assets
‪3.25%‬
Return on Equity
‪1.18%‬
Ownership
Shares Outstanding
178.06M
Float
192.39M
Held by Insiders
‪0.34%‬
Held by Institutions
‪103.75%‬
Price stats
Beta
‪0.22‬
50-Day Avg
‪90.32‬
200-Day Avg
‪89.61‬
Market Cap - 0HNC - Biomarin Pharmaceutical Inc.
Peers - 0HNC - Biomarin Pharmaceutical Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0HNCLSEBiomarin Pharmaceutical Inc.11.87BMarket Cap+13.06%52-week change3.10P/E (Trailing)‪2.14%‬Profit Margin
- 0MGBLSEGenmab A/S173.69BMarket Cap+27.59%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.34BMarket Cap+29.12%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+31.55%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.72.10BMarket Cap+82.56%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE52.61BMarket Cap+34.75%52-week change42.42P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.47%52-week change128.71P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0HNC - Biomarin Pharmaceutical Inc.
About
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatments targeting conditions such as mucopolysaccharidosis types I, IVA,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
